Treatment of primary and secondary liver malignancy

Zakiyah Kadry, N. Malekkiani, P. A. Clavien

Research output: Contribution to journalShort survey

4 Citations (Scopus)

Abstract

The management of hepatic malignancy is one of the most controversial areas in medicine. It is a continuously evolving field which requires a multimodal approach and the inclusion of a medical oncologist, a hepatobiliary surgeon, a radiotherapist, an interventional radiologist and in some cases a transplant surgeon. In addition, the recent development of novel approaches such as neoadjuvant tumour therapy, cryosurgery, thermal ablative techniques as well as biological and immunological manipulation of malignant cells has added to the complexity of this field. Today, the availability of such innovative modalities, in the absence of an extrahepatic localisation of disease, allows the potential to cure many large primary and secondary hepatic tumours. However, the appropriate use of these various treatment modalities should be limited to centers with experience in treating patients with advanced disease where innovative study protocols are available. Experience of the surgeon with difficult hepatectomies is of paramount importance. Currently, mortality following major hepatectomies in non-cirrhotic patients is below 5% in centers of reference. For example, in the series from Duke University Medical Center there were no fatalities in more than 150 liver resections in patients with benign diseases and a 2% mortality in more than 300 patients with malignant diseases. Mortality, however, reached 5% in cirrhotic patients undergoing a resection involving more than 2 segments. This review will attempt to focus on an overview of the diagnosis and treatment of a selection of more common hepatic malignancies.

Original languageEnglish (US)
Pages (from-to)338-345
Number of pages8
JournalSwiss Medical Weekly
Volume131
Issue number23-24
StatePublished - Jun 16 2001

Fingerprint

Liver
Hepatectomy
Neoplasms
Mortality
Therapeutics
Cryosurgery
Neoadjuvant Therapy
Hot Temperature
Medicine
Transplants
Surgeons
Oncologists
Radiologists

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kadry, Z., Malekkiani, N., & Clavien, P. A. (2001). Treatment of primary and secondary liver malignancy. Swiss Medical Weekly, 131(23-24), 338-345.
Kadry, Zakiyah ; Malekkiani, N. ; Clavien, P. A. / Treatment of primary and secondary liver malignancy. In: Swiss Medical Weekly. 2001 ; Vol. 131, No. 23-24. pp. 338-345.
@article{e177f68b5624404f8edb5b4fba94d300,
title = "Treatment of primary and secondary liver malignancy",
abstract = "The management of hepatic malignancy is one of the most controversial areas in medicine. It is a continuously evolving field which requires a multimodal approach and the inclusion of a medical oncologist, a hepatobiliary surgeon, a radiotherapist, an interventional radiologist and in some cases a transplant surgeon. In addition, the recent development of novel approaches such as neoadjuvant tumour therapy, cryosurgery, thermal ablative techniques as well as biological and immunological manipulation of malignant cells has added to the complexity of this field. Today, the availability of such innovative modalities, in the absence of an extrahepatic localisation of disease, allows the potential to cure many large primary and secondary hepatic tumours. However, the appropriate use of these various treatment modalities should be limited to centers with experience in treating patients with advanced disease where innovative study protocols are available. Experience of the surgeon with difficult hepatectomies is of paramount importance. Currently, mortality following major hepatectomies in non-cirrhotic patients is below 5{\%} in centers of reference. For example, in the series from Duke University Medical Center there were no fatalities in more than 150 liver resections in patients with benign diseases and a 2{\%} mortality in more than 300 patients with malignant diseases. Mortality, however, reached 5{\%} in cirrhotic patients undergoing a resection involving more than 2 segments. This review will attempt to focus on an overview of the diagnosis and treatment of a selection of more common hepatic malignancies.",
author = "Zakiyah Kadry and N. Malekkiani and Clavien, {P. A.}",
year = "2001",
month = "6",
day = "16",
language = "English (US)",
volume = "131",
pages = "338--345",
journal = "Swiss Medical Weekly",
issn = "1424-7860",
publisher = "EMH Swiss Medical Publishers Ltd.",
number = "23-24",

}

Kadry, Z, Malekkiani, N & Clavien, PA 2001, 'Treatment of primary and secondary liver malignancy', Swiss Medical Weekly, vol. 131, no. 23-24, pp. 338-345.

Treatment of primary and secondary liver malignancy. / Kadry, Zakiyah; Malekkiani, N.; Clavien, P. A.

In: Swiss Medical Weekly, Vol. 131, No. 23-24, 16.06.2001, p. 338-345.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Treatment of primary and secondary liver malignancy

AU - Kadry, Zakiyah

AU - Malekkiani, N.

AU - Clavien, P. A.

PY - 2001/6/16

Y1 - 2001/6/16

N2 - The management of hepatic malignancy is one of the most controversial areas in medicine. It is a continuously evolving field which requires a multimodal approach and the inclusion of a medical oncologist, a hepatobiliary surgeon, a radiotherapist, an interventional radiologist and in some cases a transplant surgeon. In addition, the recent development of novel approaches such as neoadjuvant tumour therapy, cryosurgery, thermal ablative techniques as well as biological and immunological manipulation of malignant cells has added to the complexity of this field. Today, the availability of such innovative modalities, in the absence of an extrahepatic localisation of disease, allows the potential to cure many large primary and secondary hepatic tumours. However, the appropriate use of these various treatment modalities should be limited to centers with experience in treating patients with advanced disease where innovative study protocols are available. Experience of the surgeon with difficult hepatectomies is of paramount importance. Currently, mortality following major hepatectomies in non-cirrhotic patients is below 5% in centers of reference. For example, in the series from Duke University Medical Center there were no fatalities in more than 150 liver resections in patients with benign diseases and a 2% mortality in more than 300 patients with malignant diseases. Mortality, however, reached 5% in cirrhotic patients undergoing a resection involving more than 2 segments. This review will attempt to focus on an overview of the diagnosis and treatment of a selection of more common hepatic malignancies.

AB - The management of hepatic malignancy is one of the most controversial areas in medicine. It is a continuously evolving field which requires a multimodal approach and the inclusion of a medical oncologist, a hepatobiliary surgeon, a radiotherapist, an interventional radiologist and in some cases a transplant surgeon. In addition, the recent development of novel approaches such as neoadjuvant tumour therapy, cryosurgery, thermal ablative techniques as well as biological and immunological manipulation of malignant cells has added to the complexity of this field. Today, the availability of such innovative modalities, in the absence of an extrahepatic localisation of disease, allows the potential to cure many large primary and secondary hepatic tumours. However, the appropriate use of these various treatment modalities should be limited to centers with experience in treating patients with advanced disease where innovative study protocols are available. Experience of the surgeon with difficult hepatectomies is of paramount importance. Currently, mortality following major hepatectomies in non-cirrhotic patients is below 5% in centers of reference. For example, in the series from Duke University Medical Center there were no fatalities in more than 150 liver resections in patients with benign diseases and a 2% mortality in more than 300 patients with malignant diseases. Mortality, however, reached 5% in cirrhotic patients undergoing a resection involving more than 2 segments. This review will attempt to focus on an overview of the diagnosis and treatment of a selection of more common hepatic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0035897829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035897829&partnerID=8YFLogxK

M3 - Short survey

C2 - 11486566

AN - SCOPUS:0035897829

VL - 131

SP - 338

EP - 345

JO - Swiss Medical Weekly

JF - Swiss Medical Weekly

SN - 1424-7860

IS - 23-24

ER -

Kadry Z, Malekkiani N, Clavien PA. Treatment of primary and secondary liver malignancy. Swiss Medical Weekly. 2001 Jun 16;131(23-24):338-345.